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1 Outline of the paper
Background on vaccination strategies
The mathematical modelling of the spread of an infection disease allows to propose control strategies to decrease the cost of the epidemic. Among such control strategies we focus in this work on the vaccination. A vaccination policy indicates when and how many people should be vaccinated in order to minimize the overall impact of the epidemic. We consider here a cost that sums the cost of the infected individuals and the cost to vaccinate the individuals (see formula (3) below for the mathematical definition). We also apply the same methodology to cost-effectiveness analysis in the context of a constrained public health budget.
State of the art and motivation
The mathematical analysis of the cost, as a function of the vaccination policy, allows to obtain an optimal vaccination strategy. Consider the epidemic in Figure 1 (see caption for the detail of the parameters) where the abscissa represents the number of the susceptible in the population, and the ordinate the proportion of infected people. In the literature several proposals for the best vaccination strategy are presented (see for example [2, 10, 23, 27] ); however previous works operated under specific assumptions on the value function (see below) and consequently did not always selected the best vaccination policy.
For instance, as we illustrate in Figure 1 the solution available in the literature is, in some cases, not optimal. The two curves represent two scenarios for an epidemic starting for an initial point X 0 . The solid curve represents the epidemic evolution when there is no vaccination (the state of the art solution for this set of parameters) and the dashed curve plots the epidemic evolution when there is some partial vaccination. The partial vaccination is seen to outperform the no vaccination policy.
For further information see the literature review in Section 2.4.
Methodology and results
Prompted by this remark we look in this work into the details of the calculation of the best vaccination strategy (using the technique of the "viscosity solutions") and note that all previous works used a specific assumption which is not always true; we explain precisely when the assumption is correct (and thus the previous works identified correctly the optimal vaccination policy) and when it is not (and in this case we describe the best vaccination policy). (1)) are presented. The epidemic starts from X 0 = (0.79, 0.0053). The parameters used are β = 73, γ = 36.5, u max = 100, r I = 1 and r V = 1.5 (see formula (3) for the meaning of the parameters r I and r V and Section 2.2 for u max ). The solid curve represents the epidemic evolution when there is no vaccination (which is the state of the art solution, see [2, 23, 27] ) and the dashed curve plots the epidemic evolution when there is some partial vaccination. The cost for the first trajectory is 0.51 and for the second is 0.49. 
Structure of the paper
The paper is organized as follows: in the next section we describe the mathematical model (section 2.1), the admissible vaccination policies (section 2.2), introduce some notations in section 2.3 and give an overview of the contributions from the literature in section 2.4; finally we present some technical obstacles in section 2.5. In section 3 several applications of the theoretical results (proved in appendixes D and E) are presented. A summary of the numerical procedure to find the best vaccination strategy is the object of section 4.
Then in section 5 we consider two applications to the optimal pertussis vaccination in adults. Finally, conclusions are the object of section 6.
Model, notations and first remarks

The model
In order to model the evolution of an epidemic, we use an SIR (SusceptibleInfected -Recovered) compartment model (cf., [6, 13, 5] for additional details).
We seek to optimize the cost of the vaccination policy; to this end denote by V (t) the proportion of people vaccinated by the time t (of course lim t→∞ V (t) ≤ 1); we consider vaccines that confer lifetime immunity so that V is an increasing function. The evolution of the disease is described by the following equations:            dX 1 (t) = −βX 1 (t)X 2 (t)dt − dV (t), X 1 (0) = X 10 , dX 2 (t) = ( βX 1 (t)X 2 (t) − γX 2 (t) ) dt, X 2 (0) = X 20 , dX 3 (t) = γX 2 (t)dt, X 3 (0) = X 30 , X 4 (t) = ∫ t 0 dV, X 4 (0) = 0.
(
Here X 1 , X 2 , X 3 , X 4 are the proportion of people in the "susceptible" respectively "infectious", "recovered" and "vaccinated" classes. Initially X 1 (0) + X 2 (0) + X 3 (0) = 1 and X 4 (0) = 0 (but X 4 need not be continuous in 0). See figure 2 for a graphical view of system (1) . Note that (1) implies X 1 (t)+X 2 (t)+ X 3 (t) + X 4 (t) = 1, ∀t ≥ 0.
Here β is the transmission rate of the disease, V is the control to be optimized and γ is the recovery rate.
We denote r V the unitary cost associated with vaccination including the cost of the vaccine and all possible side-effects and r I the unitary cost incurred by infected persons. To simplify the presentation we suppose that costs are expressed in money and postpone to Section 5 the more realistic and interesting situations when costs are expressed as medical conditions.
The cost of the disease is independent of the classes X 3 and X 4 (but dependent on the control V (t)), so we can restrict ourselves to the evolution of X 1 and X 2 . From now on a vector X will only be supposed to have two coordinates X 1 and X 2 . Denoting:
we will work under the constraints X ∈ Ω. We introduce Φ Y,dV (t) = (Φ (t)). 
This allows to conclude that the cost functional
The admissible vaccination policies
Vaccination policy dV can be modeled in different ways. Note that the proportion ∫ t 0 dV (s) of individuals vaccinated up to time "t" is increasing and ∫ t 0 dV (s) ≤ 1, ∀t ≥ 0; therefore V is a bounded variation function and dV (t) is a positive measure on [0, ∞[; this is the most general class of vaccination strategies. A restrictive class of vaccination policies will also be considered (see also the literature review in Section 2.4 below) where the speed of vaccination is bounded; in this case dV (t) = u(t)dt with u(t) ∈ [0, u max ]. Generic results (see e.g., [7] ) suggest that considering controls with bounded speed is not restrictive because the general situation is obtained in the limit u max → ∞. We will rigorously prove this assertion in appendix E and will work with the restricted class of vaccination policies until then.
We can write system (1) as:
Recall that (
T are Lipschitz functions, and V is a bounded variation function. Then using the theoretical results in [11, Section 10, Thm. 10.2.3] it is possible to conclude that (8) has a solution and the solution depends smoothly on the initial data and the control V (in L 1 norm). Let us make clear how a mathematical object such as V can be translated into vaccination policies for the unbounded case. Take for instance the trajectory Φ Y,dV (t) driven by the control (here δ t=0 is the Dirac mass in t = 0):
This means that half of the initial susceptible population Y 1 is vaccinated (instantaneously) at the onset t = 0. Then vaccination is pursued with speed of 10% percent per unit time till time t = 0.5; then no vaccination occurs. In particular this means that 50 + 0.5 × 10 = 55 percent of the population is vaccinated in all. Note that the trajectory Φ Y,dV (t) is not continuous since Φ
This trajectory can be seen as the limit when ϵ → 0 of the trajectories Φ Y,dVϵ (t) corresponding to the following vaccination policies:
Notations and first remarks
We introduce the function f :
Note that f (·, u) is a Lipschitz function with Lipschitz constant L f independent of the second argument, i.e.,
In order to define the admissible controls we consider a point Y ∈ Ω; for u max < ∞ we define:
When u max = ∞ we define: 
When u max = ∞ the previous definition is to be replaced by
The value function V umax : Ω → R is (for any u max be it bounded or not):
Any u such that J(Y, u) = V umax (Y ) is called an optimal strategy for Y ; it is not necessarily unique. However it has been proved in [10] that if u max < ∞ at least one optimal strategy exists in the set U We introduce the following notations:
Note that when γ/β > 1: A / ∈ Ω, Γ OA = Γ S and Γ A1 = ∅. Proof. Choose u = 0 then
Note that J(X, u) = 0 ∀X ∈ Γ I , ∀u ∈ U X ; using (19) we obtain V umax (X) = 0 ∀u max ∈ [0, ∞], ∀X ∈ Γ I and the continuity on Γ I . To set the value on Γ OA note that when X is such that X 1 < γ/β then Φ
Literature review
Many epidemic models have been proposed in order to describe epidemic propagation (see [6, 13, 5] for details). These models can be adapted in order to help controlling the propagation; several control options are available such as isolating infected people or immunizing susceptible people (see also [29, 10, 17] which propose combinations of these two methods). In this work we only analyze control policies that consist in the vaccination of susceptibles (immunization). The vaccination is supposed to confer lifetime (i.e., irreversible) immunity. In the context of immunization, several facts can affect the decisions of vaccination. The reference [16] discusses this problem in general, [9] proposes an approach taking the individual point of view, and [31] introduces an extension also using game theory.
The present work is on the contrary only concerned with finding an optimal vaccination strategy. Several studies have already considered this approach recasting it as an optimal control problem.
Historically one of the first to consider this problem, Abakuks explores two alternatives: in [2] a restrictive class of vaccination policies which allows at any time to immunize either all or none of the susceptible (therefore optimal policy immunizes either at once or never); in [1] the author considers policies which at any time during the course of the epidemic allow to immunize any number of the susceptible.
Abakuks proves the existence of an immunization region: within this region it is best to vaccinate with maximum effort and outside it is optimal to do nothing. The result is only obtained for u max = ∞; moreover the proof only applies to vaccination policies dV that are finite sums of Dirac masses and it is not indicated how the value function V ∞ (assumed to be continuous) behaves in the limit when Dirac masses accumulate near a point or when such masses converge to a general measure on [0, ∞[.
In another work (see [19] ) Hethcote considers a similar problem under additional constraints on the total proportion of the population affected and the maximum number of infected at the peak; the vaccination policies are taken to be stepwise constant functions and the cost of vaccination piecewise quadratic in the number of people vaccinated. He shows that the optimal strategy will be piecewise constant, with at most a single point of discontinuity.
In a similar work [23] authors consider u max = 1 and define the class of admissible policies to contain function with only isolated discontinuities. They show that the optimal strategy has a single point of discontinuity and introduce the concept of vaccination border. To do this, they assume that the value function V umax is C 1 (Ω) which, as it will be seen in the following, is not always the case (it depends on the specific choice of parameters β, γ, u max , r V , r I ).
In [29] authors set u max < ∞ for a finite horizon framework T < ∞ and work under the additional presence of a dumping term e −rt in the cost functional which reads:
) dt; moreover the infected are supposed to pay an infection cost per unit time up to the time T and nobody recovers before time T , i.e., with our notations γ = 0. They use the maximum principle to characterize the optimal policies which turn out to be of bang-bang type with only one switch.
In [20] the existence and local optimality of singular controls is investigated and using the Maximum Principle it is shown that the optimal vaccination schedule can be singular. This corresponds to our limit u max → ∞. However no information is obtained on the regularity of the value function.
In the references described so far the authors focused on the optimal strategy without studying the properties of the value function. Using a similar model and an approach via optimal control [27] finds, via a Bellman equation, that the strategy is type bang-bang (only values 0 and u max are taken). However they assume that the cost function is C 1 (Ω); finally, the results in the case where u max → ∞ are extrapolated and they suppose that the optimal strategy is bang-bang. As such the optimal policies are sometimes at odd with results in the stochastic case.
In a recent work H. Behncke (see [10] ) proves, without using that value function is C 1 (Ω), that at least one optimal strategy for the trajectory starting at X ∈ Ω is of the form u max 1I [0,θ(X)] , θ(X) ≥ 0, ∀X ∈ Ω. Although this information is very useful it does not allow to conclude on the regularity of the value function. As an illustration, we plot two situations: with parameters in figure 4 the function θ(X) is C 1 (Ω) while with parameters in figure 5 the function θ(X) is discontinuous.
Finally, without specifically entering in the context of epidemiology but using a general optimal control framework and the concept of viscosity solution the reference [32] analyzes the properties of the value function in the situation when a discount factor is present.
Considering the previous works several questions arise:
1. For which set of parameters (β, γ, u max , r V , r I ) is the value function V umax of class C 1 (Ω) and when is it less regular; note that if the value function V umax is not C 1 some vaccination strategies derived under the C 1 hypothesis will not be globally optimal.
2. Are the optimal strategies unique ?
3. What happens when u max = ∞ (i.e., when vaccination is fast with respect to the epidemic propagation).
Our work answers these questions. In particular we show that value function is not always C 1 , the optimal strategies not always unique and prove rigorously what happens in the limit u max → ∞.
Specific mathematical difficulties of the problem
The approach proposed in this work faces specific technical difficulties among which:
• There do not exist natural boundary conditions to set on some parts of the frontier (Γ 1 and Γ A1 ). This will pose problem when proving the uniqueness of the solution of the associated HJB equation. See section D.3 for the technique used to mitigate this difficulty.
• The state X is restricted to Ω while the controls e.g., in the form dV = udt, u ∈ [0, u max ] can drive it outside this domain.
• The cost function J(X 0 , dV ) has no dumping term e −rt , so we need to work in infinite horizon. This is a problem when trying to obtain Lipschitz regularity for the value function. See section D.2. We observe that θ is discontinuous.
• In general, a convenient hypothesis (cf. also [12] ) to prove the uniqueness of the viscosity solution of F(x, F (x), ∇F (x)) = 0 is that the Hamiltonian F is strictly monotone in the second argument. But here our Hamiltonians do not depend on this argument.
• In general optimal controls are unique (and the value function differentiable). Here this is not the case (cf. figure 6 ) which hints that value function has regularity defects. Figure 6 : A typical example of non-unique optimal vaccination strategy: the solid trajectory corresponds to zero vaccination while the dashed trajectory corresponds to vaccination in the colored region followed by non vaccination. But both trajectories lead to the same, minimal, cost. In this case we expect the value function to not be of class C with r ≤ r V /r I . Our starting point X 0 is in the white domain. The theoretical result states that the optimal strategy is to not vaccinate at all. To illustrate this choice we compare numerically in figure 7 the no vaccination strategy with a partial vaccination strategy. As expected the no vaccination policy is better; this result is consistent with the existing literature. approach: compute first the cost of a no vaccination strategy starting from X 0 , denoted J n . Compute then the cost of a strategy that vaccinates with maximum intensity (here u max ) from the initial time until the time θ where such that
Compare the two values: if J n ≤ J v the best strategy is to not vaccinate at all; otherwise the second strategy is the best. Numerical details are given in figure 8. In this case the initial point was in the vaccination region; previous works (see discussion in section 2.4) indicated that this point is in the no vaccination region. In figure 9 the initial point is in the vaccination region delimited by L ∂X 1 ζ rV /rI . The solid path corresponds to total vaccination, and the dashed path is partial vaccination (until trajectory exits the vaccination area). The theoretical result in appendix E.4 states that the total vaccination cost will be larger than partial vaccination, which is verified numerically (see the figure). 
Instantaneous vaccination
we plot ∂ X1 ζ(X(t)) and the reference value r V /r I (left axis of the plot) and ⟨f (X(t)), u max ), ∇∂ X1 ζ(X(t))⟩ and the reference value 0 (right axis of the plot). Vaccination stops at
The figure 10 illustrates a situation when X 0 is in the vaccination region (but outside the region delimited by L ∂X 1 ζ rV /rI ). This case is not correctly treated in the existing literature. We see in the figure that the optimal vaccination is a partial vaccination. 
Summary of optimal strategies
The previous sections show that the domain Ω is decomposed in two disjoint regions: a vaccination region and a no vaccination region. The optimal policy is to vaccinate (only) when the dynamics X(t) is in the vaccination region. In principle in order to find precisely the vaccination domain one has to solve the associated HJB equation. But, in this situation, we can build a simpler algorithm to compute the optimal vaccination policy. This algorithm is described below. It uses as inputs the values β, γ, u max , r I , r V , X 0 .
We recall that the function ζ and its derivatives are easily computed as indicated in Appendix A.
1. When u max < ∞:
the optimal vaccination policy is to not vaccinate. The overall cost is r I ζ(X 0 ). B. Otherwise the optimal vaccination policy is to vaccinate: solve numerically equation (1) with dV = u max dt and monitor
14 ii. If r V > r crit V,umax r I then compute first r I ζ(X 0 ) and denote J n = r I ζ(X 0 ) (the cost of the no vaccination policy). Also solve numerically equation (1) with dV = u max dt and monitor ∂ X1 ζ(X(t)) and ⟨f (X(t),
Denote J v this cost. Compare J n and J v and decide which cost is the best and adopt the corresponding vaccination policy.
When u max = ∞:
(a) If r V /r I ≥ 2 the optimal vaccination policy is to not vaccinate. The overall cost is r I ζ(X 0 ). (b) Otherwise, using equation (98), compute
the optimal vaccination policy is to not vaccinate. The overall cost is r I ζ(X 0 ). B. Otherwise the optimal vaccination policy is to vaccinate: find numerically (using (31)) the quantity ∆ such that Remark 4. In all situations the algorithm above solves at most once the evolution equation (1) .
Finally, Remark 2 shows that the cost functional in the equation (6) has the same optimal strategies and vaccination regions.
With respect to the existing literature the above optimal strategies are distinct in several aspects:
• when u max < ∞: previous contributions take the vaccination region to be
The strategies here will lead to lower costs.
• when u max = ∞: we do not ask full vaccination but only vaccinate the minimum proportion that allows to reach the frontier of the vaccination region.
Then we present an application to cost-effectiveness analysis.
When the vaccine has known side effects or when the illness generates severe medical conditions the money alone cannot be the only decision dimension. In this situation other techniques have to be employed. Following works in the literature we use the Quality Adjusted Life Year (QALY) and Disability-Adjusted Life Year (DALY) scales that measure the disease burden; see [33, 28, 3] and related literature for an introduction and criticism.
In the QALY scale each health state is given an utility between 1 (one year of perfect health) and 0 (death). Each individual has a number of QALY equivalent to its life expectancy in perfect health. A medical condition can reduce both the life expectancy and the quality of life and in general the QALY will combine the expected length of life and quality of life. The effect of any illness is therefore to reduce the QALY of an individual. The goal of a treatment is to increase QALY.
The DALY scale, on the contrary, measures the disease burden as disability, with 0 being no disability (perfect health) and 1 (a full year of life lost). The DALY is usually computed for an entire population and takes into account the average life expectancy at age of death in years. The goal of a health policy is to reduce the DALYs at the level of the population. DALY was introduced and is the scale of choice of the World Health Organization (WHO), see [25, 24, 14] .
Although both scales are similar, in general slight differences in numerical values are expected for a given health policy.
Optimal vaccination in presence of vaccine side-effects
We consider here an application to the optimal vaccination of pertussis with a vaccine that has identified side effects, see [26] [Chapters 1,4,5,6] and [21] . We focus more specifically on the combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap).
The vaccine side effects for adults and associated induced utility (or disabilities) are taken from [21] and reproduced in Table 1 together with the same information for the disease. Note that it is assumed that there are no deaths among adults due to pertussis (see arguments in the references for further discussion).
To summarize, the (average) DALYs induced by the vaccine are r V = 3.2605 100 ′ 000 and the DALYs of the disease are r I = 3511 100 ′ 000 . As a remark, the illness seems to be ≃ 1000 times less desirable than the vaccine.
The goal is to find a vaccination strategy that minimizes the overall DALY burden, which is equivalent to minimizing functional J in equation (3) .
As an illustration we consider an outbreak of pertussis. The generally admitted propagation parameters are γ = 1/21, R 0 = β/γ = 15.7 (thus β = 0.75), see for instance [4] [pages 1055-1056] and [18] [pages 640-641].
Consider now an epidemic starting from a pool of 100 infected individuals in a susceptible population of 65 Millions individuals among which 10% are susceptible. Thus X 10 = 0.1 and X 20 = 100/(6.5 * 10 7 ) = 1.54 * 10 −6 . We consider first that the vaccination can be implemented very fast which, with our notations, means u max = ∞. Using the theoretical results of previous sections it appears that it is optimal to vaccinate 4.657% percent of the population. At the end of the vaccination there is still 5.343% ≤ 1/R 0 = 6.36% percent of the population susceptible. If on the contrary only 1% of the population can be vaccinated in a month, then u max = 0.12 and it is optimal to vaccinate until the susceptible population is 5.344%. In this case 4.656% percent (Susceptible) have been vaccinated and 5.987 * 10 −5 % percent were infected before vaccination stopped. In both cases vaccination avoids 142708 DALY.
Cost-effectiveness analysis
A different perspective in vaccination programs arises when a vaccine without notable side effects (but an economic cost, expressed in $) is to be compared with other possible public health programs. In this case the money allocated to the vaccine campaign cannot be allocated to other projects. The optimal vaccination is found through a cost-effectiveness analysis, adapted below to our SIR model. We emphasize that what follows is a simple deterministic description and in practice additional tools, related to societal parameters and uncertainties have to be taken into account.
Suppose that the available public health budget is B $ and that other projects spend ρ$ in order to avert one DALY. The goal is to find the optimal vaccination policy which, combined with all other health programs, maximize the total DALY averted for the given budget B $ . As above, r I will be the DALY lost by an infected individual and r Q V to be the (economic) cost of implementing one vaccine; the total DALYs averted with budget B $ including vaccination with policy dV are:
) .
(20) Algebraic manipulations indicate that the maximization of J Q is equivalent to the minimization of the cost functional J in equation (3) if we set r V = r Q V /ρ. Note that in this case both r I and r V are expressed in DALY (not $).
As an application we consider again the pertussis vaccination for adults as an addition to the traditional multi-valent vaccines administered during the childhood.
Although no consensus for the value of ρ exists, the World Health Organization, through its CHOICE program (see [14, 30, 15] ) considers that for a country with a Gross Domestic Product (GDP) per capita of g$, a public health project is considered cost-efficient when it saves at least one DALY for each g$ invested. Many countries in the African "low income" zone have g around 400$ (United Nations 2013 data: Ethiopia, Madagascar,...). We set the threshold at ρ = 400$ per DALY averted. For the cost of the implementation of the vaccine we follow [22] [Chapter 2, page 44 and Table 20 Note that the initial point is precisely in a region where previous analyses in the literature would conclude that optimal strategy is no vaccination.
At the end of the vaccination period the epidemic is still not contained because 6.424% > 1/R 0 = 6.36%. Why does the vaccination stops while the epidemic still expands ? To understand this, consider first the quotient r Q V /r I = 569.63 which is above the threshold value ρ = 400. This means that vaccination, seen as "treatment", is not cost-effective. But vaccination, even at high costs, can reduce the propagation of the epidemic, creating herd immunity and saving more than the vaccinated individual. As such, when the epidemic is large in size, vaccination becomes, temporarily, more cost-efficient than other public health programs. This is precisely what happens here. On the contrary, when the Susceptible approach 1/R 0 the vaccination creates less herd immunity and its cost becomes a limitation.
The figure 11 illustrates the optimal vaccination policy in terms of classical cost-effectiveness analysis. ,X20) ) . In this very particular setting, both costs are initially above the threshold ρ. The theoretical result guarantees that, if the available budget is large enough to traverse the initial, "above the threshold" region, both curves will be below the threshold ρ at the end of the vaccination. In fact the vaccination stops when the marginal cost reaches ρ the second time.
Conclusion
We analyze in this work the optimal vaccination policy in a SIR model. The theoretical results allow to compute the global optimum without any smoothness hypothesis; from the technical point of view we show that the value function is the unique solution of a Hamilton-Jacobi-Bellman equation. As previous studies indicate, the Susceptible-Infected plane is divided in two regions: one vaccination region and one non-vaccination region. This partition is proven to be globally optimal.
Several applications are considered: first some toy examples when the costs are expressed as economic values. Then we consider pertussis vaccination in adults when the vaccine has side-effects and the optimal policy maximizes the DALYs averted. A final application, still in the framework of pertussis vaccination in adults, considers the optimal vaccination with constraints on the public health budget. The theoretical results are particularly relevant in this situation not adequately considered in the literature: the performance of a vaccination policy does not only depend on the marginal cost per DALY averted, but also on the long term herd immunity effects created. The model is able to predict when the long term effects will offset the initial expense to the point that makes vaccination cost-effective.
Appendix
A Properties of the number of infected people without vaccination
We recall some properties of the number of infected people in absence of vaccination. The reader can also consult [2, 1] . Consider the model without control: 
Moreover ζ(X) > X 1 − γ β , ∀X ∈ Ω and ζ ∈ C 1 (Ω).
Remark 5. Although ζ depends on X, when there is no ambiguity, we will just write ζ.
2 (t). Straightforward computations allow to prove that:
Or
1 we obtain equation (22) .
Let 
where for the last inequality we used that e 1−1/z −z ≤ 0 for any z = Remark 6. Thanks to (22) we obtain by the implicit function Theorem that ζ has continuous derivatives around any X ∈ Ω; we can calculate first and second partial derivatives of ζ with respect to X 1 and X 2 :
20
Note that since ζ > X 1 − γ β all fractions are well defined and ζ is even C 2 (Ω).
B Properties of the trajectories
Lemma B.1.
is decreasing along trajectories of the system (21). Proof. We have to prove that:
Using the expression of ζ, we have:
. Equation (29) can thus be rewritten as follows:
Using equations (27) and (28), this gives after some computations: X 1
> 0 which is always true because X 1 is strictly positive and ζ ̸ = X 1 − γ β .
Lemma B.2. For all
Proof. For Γ 1 , the scalar product with the incoming normal is positive:
Proof. Since J 0 = r I ζ the conclusion follows from Lemma A.1.
Lemma B.4. For all X ∈ Ω, we have
Proof. Using expression in (25) , to prove ∂ X1 ζ ≤ 2, we just have to show that
. For that, we take same notation and result as in the proof of the Lemma A.1 so X 1 ≥ γ β and we denote ξ =
. We have to prove
With these notations, we have F (ξ, X 1 , X 2 ) = e As e
, this proves that F (ξ, X 1 , X 2 ) ≤ 0.
Lemma B.5. The level lines defined by L
and have point A = (
and (28) we have:
Then, we replace in (22) 
C An introduction to viscosity solutions
This section is largely based on classical works such as [12] , [7] , [8] [32] . We refer the reader to these works for additional details.
Let ξ : O → R be a scalar function defined on an open set O ⊆ R n .
Definition C.1. The set of super-differentials of ξ at a point x ∈ O is:
Similarly, the set of sub-differentials of ξ at a point x ∈ O is:
We will also use the following:
Lemma C.1. Let ξ ∈ C(O). Then
p ∈ D + ξ(x) if and only if there exists a function ϕ ∈ C 1 (O) such that ∇ϕ(x) = p and ξ − ϕ has a local maximum at x.
p ∈ D − ξ(x) if and only if there exists a function ϕ ∈ C 1 (O) such that ∇ϕ(x) = p and ξ − ϕ has a local minimum at x.
In the following, we consider the first order partial differential equation:
defined on an open set O ∈ R n . Here, F : O × R n × R n → R is a continuous (possibly nonlinear) function.
Definition C.2. A function ξ ∈ C(O) is a viscosity subsolution of (35) if
Similarly, ξ ∈ C(O) is a viscosity supersolution of (35) if
Finally, we call ξ a viscosity solution of (35) if it is both a supersolution and a subsolution in the viscosity sense.
Remark 7. For each particular problem we explicitly specify the boundary conditions.
D Bounded vaccination speed (u max < ∞)
In this section we assume that u max < ∞. Proof. We first prove that for a fixed control u and time t the function
D.1 Properties of the value function
is Lipschitz with the Lipschitz constant independent of u. We write:
|| where L f is the constant in equation (12) . Then:
Using the Gronwall Lemma and taking the square root, we obtain: 
Note that u Y is member of the compact set {u :
Thus the constant C uY ,Tmax only depends on T max (and not on Y or Z). Changing the roles of Y and Z we obtain the reverse inequality thus the conclusion. 
where we used the fact that X ∈ Γ I implies V umax (X) = 0 and that V umax is positive. From now on we continue as above and obtain the Lipschitz property for Y and Z.
Since V umax is a Lipschitz function on Ω with bounded Lipschitz constant it admits a unique Lipschitz extension over Ω.
D.2 The HJB equation and value function
Theorem D.2. The value function V umax is a viscosity solution of the HamiltonJacobi-Bellman (HJB) equation:
Remark 8. There is no boundary condition on Γ A1 .
Remark 9. See appendix C for an introduction to viscosity solutions.
Proof. Using Lemma C.1 and Definition C.2 we first show that V umax is a subsolution of (39) then we will show it is also a supersolution.
Step
24
We will prove that:
This is equivalent to:
Assume that it is not the case. Then there exists, by continuity, a value w ∈ [0, u max ] (see Remark 10 page 27 below) and a constant κ > 0 such that in a neighborhood of Y :
Or, by the definition of the optimality of V umax in Y :
by summing the inequality we get 0 < −κδ, which is absurd. Therefore using Lemma C.1 we obtain:
To prove (39e) we use appendix B where we prove that trajectories Φ Y,u (·) with Y ∈ Γ 1 are strictly entering the domain Ω for all w
Moreover, we choose φ such that φ is C(Ω) and C 1 (Ω). These arguments allow to prove equation (45) from equation (44). Moreover the same proof can be used for all X ∈ Γ 1 and we obtain:
By Lemma 2.1, we have that V umax is bounded on Ω and by Theorem D.1 V umax is a Lipschitz function. By definition of V umax we have V umax (X) = 0 on Γ I and Γ OA . So V umax is a subsolution of (39).
Step 2. Now we prove that V umax is a supersolution of (39). 
So, for any w, we have:
Taking the infimum with respect to w we obtain V umax (Y ) ≥ V umax (Y )+κδ. This is absurd, therefore V umax is a supersolution on Ω. For the same reasons as previously, we have −H umax (X, ∇V umax (X)) ≥ 0 on Γ 1 and V umax is a supersolution of equation (39).
Step 3. To summarize this proof, we showed that:
-V umax is both a subsolution and a supersolution of (39b) and (39e),
So V umax is a viscosity solution of the Hamilton-Jacobi-Bellman equation (39).
D.3 Uniqueness of the solution of the HJB problem
Theorem D.3. Let F 1 be a subsolution of (39) and F 2 a supersolution. Then:
Remark 10. In the following, we will use that, for any A 1 , B 1 , A 2 , B 2 ∈ R with min(A 1 , B 1 ) ≤ min(A 2 , B 2 ) there exists ρ ≥ 0 such as:
Proof. Let B α ∈ Ω denote the point with coordinates (1 − α, α) and:
Let D α ⊂ Ω be the domain strictly bounded by Γ I , Γ OA , Γ ABα and Γ Bα1 , see figure 12 for a graphical representation. When γ/β ≥ 1 the point A will lie outside Ω, we take D α = Ω, Γ ABα = ∅ and Γ Bα1 = Γ 1 . We prove in appendix B that for any X 0 ∈ ∂D α the trajectory Φ X0,w (t) with
For X ∈ Γ Bα1 , X ̸ = (1, 0), the scalar product with the incoming normal is positive:
For X ∈ Γ ABα , X ̸ = (1, 0), the relevant quantity is:
We now show the Theorem for F 1 and F 2 restricted to D α . To this end we make the change of variable introduce by Kružkov (see [7] ), for X ∈ D α , W(X) = 1 − e −F(X) . Formally:
thus ∇F(X) =
∇W(X)
(1−W(X)) . This motivates the introduction of the following Hamiltonian:
Since 1−W(X) will always be positive, for convenience, we conclude the demonstration using the Hamiltonian:
So we have to prove the following:
Lemma D.4. Let the Hamilton-Jacobi-Bellman equation:
(PW)
If W 1 is a subsolution of (50) and W 2 a supersolution, then
Proof. Suppose now that the Lemma is not true, then there exists σ > 0 such that: sup
For any ϵ this function has a global maximum in (x
ϵ , y ϵ ) and we have for ϵ small enough: Ψ ϵ (x ϵ , y ϵ ) ≥ σ/2 > 0. Since W 1 , W 2 are bounded we obtain also lim ϵ→0 |x ϵ − y ϵ | = 0. In addition, consider the functions:
and W 1 is a subsolution of (50). Using the Lemma (C.1), we have:
Similarly, using that the application y → W 2 (y) − φ 2 (y) has its maximum in y ϵ , φ 2 is C 1 (Ω φ2 ) and W 2 is a supersolution of (50), we have −H
Combining these two equations, we obtain:
We use then Remark 10, withH umax written as:
So we obtain after few simplifications and factorisation (ρ is the constant given by Remark 10):
. Since W 2 is uniformly continuous (as a continuous function on a compact) and lim ϵ→0 |x ϵ − y ϵ | = 0, we have:
So,
After eventually extracting a subsequence (ϵ n ) n≥0 we can suppose that lim ϵn→0 x ϵn = lim ϵn→0 y ϵn = x. Note that x 1 = 0 or x 2 = 0 would imply
and (56). Therefore x 1 ̸ = 0 and x 2 ̸ = 0.
We can therefore rewrite (55) as follows:
Since r I , r V , β > 0, ρ ≥ 0 and x 1 ̸ = 0, x 2 ̸ = 0 this implies that:
On the other hand, for ϵ relatively small, we have
This proof is also available for X ∈ Γ 1 . For Γ OA and Γ I , we just use the value of the function.
Theorem D.5. The value function V
umax is the unique solution of the HJB problem (39).
Proof. Let F 1 and F 2 be two viscosity solutions of (39). Since F 1 is a subsolution and F 2 is a supersolution, we have, by Theorem D.3 that
Interchanging the roles of F 1 and F 2 , we can conclude F 2 ≤ F 1 . So F 1 = F 2 on Ω and therefore on Ω (by continuity).
Thus the solution is unique. By Theorem D.8 the value function V umax is the unique solution.
D.4 Solution candidate and its properties: the sub-critical case
Theorem D.5 implies that in order to find the value function it is enough to find a solution of the HJB equation (39). We expect the solution to lead to a partition of the domain into a vaccination region and a non-vaccination region. An important question concerns the regularity of the value function which at its turn is related to the uniqueness of the optimal strategy. The frontier of the vaccination region will be seen to be related to the level line L rV /rI that contain such points will lead to non unique optimal strategies (and non smooth value functions).
When γ/β < 1, for any u max < ∞ we introduce the critical point X crit umax which is the unique solution of the equations:
The proof of existence and uniqueness of X crit umax is left as an exercise for the reader. One can use the description of the curve ⟨f (X, u max ), ∇∂ X1 ζ(X)⟩ = 0 (see also the Appendix A for formulaes involving ζ and its derivatives) to show that X crit umax = (x * , 1 − x * ) where x * is the solution of:
.
(60) Then the value r crit V,umax is defined as
For γ/β ≥ 1 we set r 
The level line L Proof. In order to prove that the trajectory Φ X0,w (t) enters the domain Ω
N V umax
it is enough to prove that the tangent to the trajectory has strictly positive scalar product with the incoming normal at X 0 to Ω N V umax i.e.,
This follows (after some straightforward computations) from the definition of r Introduce also the control u X0 (t) taken to be u max as long as the trajectory Φ X0,uX 0 (·) (t) obtained with this control u X0 (t) remains in Ω V umax (and zero otherwise). It is a feedback control. Formally it is the solution of the equation:
The fact that such a solution exists is a consequence of the regularity of the boundary of Ω 
is the unique viscosity solution of the following problem: Here H vac,umax : Ω × R 2 → R is the Hamiltonian function:
Π rV ,rI umax is a solution of the HJB equation (39).
Proof. We only consider in this proof the circumstance when γ/β < 1, because proof for γ/β ≥ 1 is similar to the proof for γ/β < 1. 
Another way to prove the result is to parametrize the boundary curve with a parameter α 1 and denote α 2 the time required to reach the curve. Using the regularity properties of the ODE the function is C 1 in parameters (α 1 , α 2 ) and the change of coordinates from X to (α 1 , α 2 ) is regular around each point in the interior of Ω coincide on the common frontier it follows that the tangential derivatives along the frontier are the same. Let us prove that the directional derivative also coincide in the direction f (X, u max ), which can be written:
We used above the fact that J 0 = r I ζ satisfies 
Equation (69) is a simple consequence of (62) , we will prove that in addition:
Consider X 0 ∈ L
umax that reaches the frontier at time t > 0 and point X 0 which can be written: Φ Y,umax (t) = X 0 . Formally
From now on we will drop the notation Φ Y,umax (τ ) and only denote ( 
But this latter quantity is integrable over [0, t] and after classical arguments we obtain that 
dτ.
Thus, we obtain
Similar computations allow to write: 
D.5 Solution candidate and its properties: the super-critical case
We work here under the hypothesis r V ≥ r crit V,umax . In particular this implies γ/β < 1.
The simplest case is when r V ≥ 2r I and will be dealt with directly later in Theorem D.12. On the contrary, the situation when r V ∈ [r crit V,umax r I , 2r I [ requires some more work. In this case the value function V umax will not be C 1 . Define (see also figure 14 ):
Using the formulas for f and the derivatives of ζ one can prove with straightforward computations:
• Γ crit sub is connected; denote by P crit rV the other extremity of the curve; then
• the trajectories starting from points on the curve Γ crit sub enter the domain
• the trajectories starting from points in L
We note that the previous properties imply that t X0 > 0; indeed, take Z = Φ Y,umax (−ϵ) for ϵ small enough; then integrating over the curve τ → Φ Z,umax (τ ) we obtain:
Developing the last term and using the HJB equation satisfied by J 0 we can write:
The curve τ → Φ Z,umax (τ ) belongs to the domain where
Y,umax (−ϵ) satisfies the inequality in the equation (76) and as such we obtain t Y ≥ ϵ > 0.
We define a curve Γ crit super as:
The curves Γ 
Therefore we also have: 
is the unique viscosity solution of the following problem: Moreover, as before, one can prove that Π rV ,rI umax is C 1 on Γ crit sub . Another alternative is to repeat the arguments used to prove that the value function is Lipschitz (here the control has the same structure: it has value u max from 0 to some finite time and then 0). 
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E Instantaneous vaccination
Recall that for u max = ∞ the value function is denoted as V ∞ ; also consult equation (17) for the definition of H ∞ . The following result connects the bounded and unbounded control problems (see also [7] pages 113-115 for generic related results):
Theorem E.1. The sequence (V umax ) umax≥0 is decreasing and
Moreover the convergence is uniform over compacts of Ω and V ∞ is Lipschitz over Ω. 
Proof. We will use the same arguments and notations as in the proof of the Theorem D.2.
Step 1. First, we prove that V ∞ is a subsolution of (87b). We take the same notations and the same reasoning as in the case u max < ∞. So equation (42) Remark 10 page 27 assures that there exists ρ ≥ 0 such that:
Here, we choose the control ρ on the interval [0, δ] and for the same reasons as above, we obtain:
In particular, by the optimality of V ∞ on Y , we have:
And we can conclude as above that V ∞ is solution of equation (87).
Step 2. We prove that V ∞ is a supersolution of (87). Using the same notations and reasoning as in the proof for u max < ∞ equation (46) 
E.2 Uniqueness of the solution of the HJB problem.
Theorem E.3. Let F 1 a subsolution of (87) and F 2 a supersolution. Then:
Proof. We use the same notation and reasoning as in the proof in Section D.3. The Hamiltonian used here is: And for the same reasons as in the proof for u max bounded we obtain instead of (57):
We can conclude as when u max is bounded.
E.3 A candidate value function: the sub-critical case
We introduce the critical point value r crit V,∞ :
We see (after some computations) that r 
